AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
DIabetic Retinopathy Candesartan Trials
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4717
- Registration Number
- NCT00252694
DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2009-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1600
- Registration Number
- NCT00252863
- Locations
- 🇩🇪
Research Site, Zwickau, Germany
GALLANT 22 Tesaglitazar vs. Placebo
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 475
- Registration Number
- NCT00252837
- Locations
- 🇸🇪
Research Site, Åmål, Sweden
ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2007-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 44
- Registration Number
- NCT00252798
- Locations
- 🇦🇺
Research Site, East Melbourne, Victoria, Australia
Iressa 2nd Line Phase III Study in Japan
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 484
- Registration Number
- NCT00252707
- Locations
- 🇯🇵
Research Site, Yamagata, Japan
GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2000
- Registration Number
- NCT00252876
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Iressa Case Control Study in Japan
Completed
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2011-01-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6000
- Registration Number
- NCT00252759
- Locations
- 🇯🇵
Research Site, Toyama, Japan
DIabetic Retinopathy Candesartan Trials.
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2014-06-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1850
- Registration Number
- NCT00252720
GALLANT 8 Tesaglitazar Add-on to Metformin
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 555
- Registration Number
- NCT00251953
- Locations
- 🇬🇧
Research Site, Wrexham, United Kingdom
ASTERIX: Low Dose ASA and Nexium
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 960
- Registration Number
- NCT00251966
- Locations
- 🇬🇧
Research Site, Edinburgh, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath